Dergiler / Turkish journal of nephrology (Online) / 2019 / Cilt: 28 - Sayı: 2

Therapeutic Plasma Exchange in Renal Diseases: A Three-Year Retrospective Analysis

Sayfa
114–119
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Six patients (12.7%) treatedwith plasmapheresis died because of primary disease.Conclusion: Plasmapheresis has place as a therapeutic modality in nephrology practice with a minor adverse reactions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of the study was to analyze the indications, efficacy, and complications of therapeutic plasma exchange(plasmapheresis) applied for renal diseases in three years retrospectively.Materials and Methods: This study included 47 patients with nephrological disorders (41.5%, 28 men and 19 women).
📊
Temel Bulgular & Veri:Weanalyzed data including demographic characteristics, underlying renal disease, and outcomes of the patients as well as theprocedural characteristics and safety profile regarding the type and amount of the replacement fluid, number of sessions,and complications.Results: The mean age of the patients was 48±14.68 years.
💡
Sonuç & Katkı:Six patients (12.7%) treatedwith plasmapheresis died because of primary disease.Conclusion: Plasmapheresis has place as a therapeutic modality in nephrology practice with a minor adverse reactions.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The aim of the study was to analyze the indications, efficacy, and complications of therapeutic plasma exchange(plasmapheresis) applied for renal diseases in three years retrospectively.Materials and Methods: This study included 47 patients with nephrological disorders (41.5%, 28 men and 19 women). Weanalyzed data including demographic characteristics, underlying renal disease, and outcomes of the patients as well as theprocedural characteristics and safety profile regarding the type and amount of the replacement fluid, number of sessions,and complications.Results: The mean age of the patients was 48±14.68 years. A total of 251 sessions were performed, and the mean number ofsessions per patient was 5.61±2.79. Nephrological diseases treated with plasmapheresis were rapidly progressive glomerulonephritis in 17 (36.4%) patients, thrombotic microangiopathies in 13 (27.6%) patients, renal transplantation in 9 (19%)patients, focal segmental glomerulosclerosis in 4 (8.5%) patients, and multiple myeloma in 4 (8.5%) patients. The mostcommon complications were muscle cramps in 8.5% of patients, minor allergic reactions and pruritus in 6.3% of patients,hypotension in 6.3% of patients, and hematoma in catheter insertion site in 2.1% of patients. Six patients (12.7%) treatedwith plasmapheresis died because of primary disease.Conclusion: Plasmapheresis has place as a therapeutic modality in nephrology practice with a minor adverse reactions.

🔖

Bu Makaleye Atıf Yap

ERSAN, S., LİV, F., SEZER, S. D., ÇOLAK, H., ALP, A., CEYLAN, C., AKAR, H. (2019). Therapeutic Plasma Exchange in Renal Diseases: A Three-Year Retrospective Analysis. Turkish journal of nephrology (Online), Cilt: 28 - Sayı: 2, 114–119. https://ajindex.com/articles/374952

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Sabath E, Denker B M: Plasmapheresis. In: Brenner and Rector’s (eds), The Kidney. Philadelphia: Elsevier, 2016; 2148-64
  2. Sengul Samanci N, Ayer M, Gursu M, Ar MC, Yel K, Ergen A, et al. Patients treated with therapeutic plasma exchange: A single center experience. Transfus Apher Sci 2014; 51: 83-9. [CrossRef] 3. Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 2014; 18: 41-9. [CrossRef] 4. Visvardis G, Manou E, Griveas I, Meimaridou D, Mitsopoulos E, Kyriklidou P, et al. Therapeutic apheresis of immune diseases in nephrology department. Ren Fail 2004; 26: 569-74. [CrossRef] 5. Bambauer R, Latza R, Burgard D, Schiel R. Therapeutic Apheresis in Immunologic Renal and Neurological Diseases. Ther Apher Dial 2017; 21: 6-21. [CrossRef] 6. Sanchez AP, Ward DM. Therapeutic apheresis for renal disorders. Semin Dial 2012; 25: 119-31. [CrossRef] 7. Aydin Z, Gursu M, Karadag S, Uzun S, Tatli E, Sumnu A, et al. Role of plasmapheresis performed in hemodialysis units for the treatment of anti-neutrophilic cytoplasmic antibody-associated systemic vasculitides. Ther Apher Dial 2011; 15: 493-8. [CrossRef] 8. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31: 149-62. [CrossRef] 9. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28: 145-284. [CrossRef] 10. Public Health Services Price Schedule. http://tig.saglik.gov.tr/ TR,26173/kamu-saglik-hizmetleri-fiyat-tarifesi-guncellenmistir. html 11. Pagnoux C. Plasma exchange for systemic lupus erythematosus. Transfus Apher Sci 2007; 36: 187-93. [CrossRef] 12. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schönlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol 2007; 22: 1167-71. [CrossRef] 13. Katz VL, Watson WJ, Thorp JM Jr, Hansen W, Bowes WA Jr. Treatment of persistent postpartum HELLP syndrome with plasmapheresis. Am J Perinatol; 9: 120-2. [CrossRef] 14. Esplin MS, Branch DW. Diagnosis and management of thrombotic microangiopathies during pregnancy. Clin